Promising antisense drug could alter Dravet syndrome in children
An early-stage trial suggests the antisense drug zorevunersen is safe for children with Dravet syndrome and may dramatically reduce seizures, with the highest-dose group seeing 59%–91% fewer seizures after about 20 months and potential neurodevelopmental and quality-of-life benefits. The study involved 81 children (ages 2–18) in the UK and US and did not include a placebo; larger, controlled trials are underway, with results expected by 2028 to determine if the treatment can alter the disease course.
